Inflammatory and Metabolic Dysregulation and the 2-Year Course of Depressive Disorders in Antidepressant Users

Scarce evidence suggests that inflammatory and metabolic dysregulation predicts poor response to antidepressants, which could result in worse depression outcome. This study prospectively examined whether inflammatory and metabolic dysregulation predicted the 2-year course of depressive disorders among antidepressant users. Data were from the Netherlands Study of Depression and Anxiety, including 315 persons (18–65 years) with a current depressive disorder (major depressive disorder, dysthymia) at baseline according to the DSM-IV criteria and using antidepressants. Inflammatory (C-reactive protein, interleukin-6 (IL-6), tumor-necrosis factor-α) and metabolic (waist circumference, triglycerides, high-density lipoprotein (HDL) cholesterol, blood pressure, fasting glucose) factors were measured at baseline. Primary outcome for course of depression was indicated by whether or not a DSM-IV depressive disorder diagnosis was still/again present at 2-year follow-up, indicating chronicity of depression. Elevated IL-6, low HDL cholesterol, hypertriglyceridemia, and hyperglycemia were associated with chronicity of depression in antidepressant users. Persons showing ⩾4 inflammatory or metabolic dysregulations had a 1.90 increased odds of depression chronicity (95% CI=1.12–3.23). Among persons who recently (ie, at most 3 months) started antidepressant medication (N=103), having ⩾4 dysregulations was associated with a 6.85 increased odds of depression chronicity (95% CI=1.95–24.06). In conclusion, inflammatory and metabolic dysregulations were found to predict a more chronic course of depressive disorders among patients using antidepressants. This could suggest that inflammatory and metabolic dysregulation worsens depression course owing to reduced antidepressant treatment response and that alternative intervention treatments may be needed for depressed persons with inflammatory and metabolic dysregulation.

[1]  B. Penninx,et al.  Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. , 2011, The American journal of psychiatry.

[2]  A. Beekman,et al.  Obesity and onset of significant depressive symptoms: results from a prospective community-based cohort study of older men and women. , 2010, The Journal of clinical psychiatry.

[3]  A. Leventhal,et al.  Efficacy and Effectiveness of Antidepressants: Current Status of Research , 2010, Psychotherapy and Psychosomatics.

[4]  M. Maes,et al.  Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice , 2000, Psychiatry Research.

[5]  A. King,et al.  Depression and the Metabolic Syndrome in Young Adults: Findings From the Third National Health and Nutrition Examination Survey , 2004, Psychosomatic medicine.

[6]  A. Beekman,et al.  The three-year naturalistic course of major depressive disorder, dysthymic disorder and double depression. , 2009, Journal of affective disorders.

[7]  M. Trivedi,et al.  Pro-Inflammatory Cytokines as Predictors of Antidepressant Effects of Exercise in Major Depressive Disorder , 2012, Molecular Psychiatry.

[8]  H. Vedder,et al.  Cytokine Production and Treatment Response in Major Depressive Disorder , 2000, Neuropsychopharmacology.

[9]  E. Maron,et al.  Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. , 2008, Progress in neuro-psychopharmacology & biological psychiatry.

[10]  R. Blakely,et al.  The Proinflammatory Cytokines Interleukin-1beta and Tumor Necrosis Factor-Alpha Activate Serotonin Transporters , 2006, Neuropsychopharmacology.

[11]  M. Schwarz,et al.  Psychotropic Effects of COX-2 Inhibitors - A Possible New Approach for the Treatment of Psychiatric Disorders , 2004, Pharmacopsychiatry.

[12]  J. Suls,et al.  Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-Analysis , 2009, Psychosomatic medicine.

[13]  W. Banks,et al.  Penetration of interleukin-6 across the murine blood-brain barrier , 1994, Neuroscience Letters.

[14]  L. Groop,et al.  Association between depressive symptoms and metabolic syndrome is not explained by antidepressant medication: Results from the PPP-Botnia Study , 2012, Annals of medicine.

[15]  B. Ainsworth,et al.  International physical activity questionnaire: 12-country reliability and validity. , 2003, Medicine and science in sports and exercise.

[16]  An Pan,et al.  Bidirectional Association Between Depression and Metabolic Syndrome , 2012, Diabetes Care.

[17]  M A Buist-Bouwman,et al.  Functional disability of mental disorders and comparison with physical disorders: a study among the general population of six European countries , 2006, Acta psychiatrica Scandinavica.

[18]  Volker Arolt,et al.  The Interleukin 1 Beta (IL1B) Gene Is Associated with Failure to Achieve Remission and Impaired Emotion Processing in Major Depression , 2010, Biological Psychiatry.

[19]  A. Beekman,et al.  Association of depressive disorders, depression characteristics and antidepressant medication with inflammation , 2012, Translational Psychiatry.

[20]  A. Baker,et al.  Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis , 2012, Psychological Medicine.

[21]  E. Maron,et al.  Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[22]  D. Anderson,et al.  The relationship between abdominal obesity and depression in the general population: A systematic review and meta-analysis. , 2011, Obesity research & clinical practice.

[23]  Charles L. Raison,et al.  Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression , 2009, Biological Psychiatry.

[24]  Debbie A Lawlor,et al.  Exercise for depression , 2013, The Cochrane database of systematic reviews.

[25]  M. Marmot,et al.  Anti-depressant medication use and C-reactive protein: Results from two population-based studies , 2011, Brain, Behavior, and Immunity.

[26]  S. Bandinelli,et al.  Metabolic depression: a chronic depressive subtype? Findings from the InCHIANTI study of older persons. , 2011, The Journal of clinical psychiatry.

[27]  F. Zitman,et al.  Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use , 2009, Acta psychiatrica Scandinavica.

[28]  C. Mathers,et al.  Projections of Global Mortality and Burden of Disease from 2002 to 2030 , 2006, PLoS medicine.

[29]  D. Fuchs,et al.  Chronic immune stimulation correlates with reduced phenylalanine turnover. , 2008, Current drug metabolism.

[30]  M. Bloch,et al.  The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis , 2011, Neuropsychopharmacology.

[31]  D. F. Drake,et al.  A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. , 2013, JAMA psychiatry.

[32]  F. Zitman,et al.  Personality traits and childhood trauma as correlates of metabolic risk factors: The Netherlands Study of Depression and Anxiety (NESDA) , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[33]  A. Beekman,et al.  Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression , 2013, Molecular Psychiatry.

[34]  A. Mack.  Prevalence, Persistence, and Sociodemographic Correlates of DSM-IV Disorders in the National Comorbidity Survey Replication Adolescent Supplement , 2013 .

[35]  D. Mehta,et al.  Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression , 2013, Brain, Behavior, and Immunity.

[36]  N. Herrmann,et al.  A Meta-Analysis of Cytokines in Major Depression , 2010, Biological Psychiatry.

[37]  S. Tsai,et al.  Association Study of the Interleukin-1beta (C-511T) Genetic Polymorphism with Major Depressive Disorder, Associated Symptomatology, and Antidepressant Response , 2003, Neuropsychopharmacology.

[38]  Willem A. Nolen,et al.  Duration of major depressive episodes in the general population: Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS) , 2002, British Journal of Psychiatry.

[39]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. , 2006, Current opinion in cardiology.

[40]  Constantine G. Lyketsos,et al.  The Life Chart Interview: A standardized method to describe the course of psychopathology. , 1994 .

[41]  R. Eckel,et al.  The metabolic syndrome and inflammation. , 2004, Metabolic syndrome and related disorders.

[42]  H. Möller,et al.  The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine , 2006, Molecular Psychiatry.

[43]  P. Cuijpers,et al.  Two-year course of depressive and anxiety disorders: results from the Netherlands Study of Depression and Anxiety (NESDA). , 2011, Journal of affective disorders.

[44]  L. Niskanen,et al.  Association of depressive symptoms and metabolic syndrome in men , 2009, Acta psychiatrica Scandinavica.

[45]  B. Nicklas,et al.  Effects of exercise on adipokines and the metabolic syndrome , 2008, Current diabetes reports.

[46]  I. Craig,et al.  Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study: Differentiating between Baseline ‘Predictors’ and Longitudinal ‘Targets’ , 2013, Neuropsychopharmacology.

[47]  D. Fuchs,et al.  Neopterin production, tryptophan degradation, and mental depression—What is the link? , 2002, Brain, Behavior, and Immunity.

[48]  George Mendelson,et al.  Book Reviews , 1995 .

[49]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.

[50]  F. Zitman,et al.  Sociodemographic and psychiatric determinants of attrition in the Netherlands Study of Depression and Anxiety (NESDA). , 2012, Comprehensive psychiatry.

[51]  Kerry Dwan,et al.  Exercise for depression , 2014 .

[52]  H. Wittchen.  Reliability and validity studies of the WHO--Composite International Diagnostic Interview (CIDI): a critical review. , 1994, Journal of psychiatric research.

[53]  P. Cuijpers,et al.  The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods , 2008, International journal of methods in psychiatric research.